RegulatoryCompany release
FDA grants Breakthrough Therapy status to daretabart for newly diagnosed high-risk neuroblastoma in children
Essential Pharma · Mon 16 Nov 2026
Renaissance Pharma, part of Essential Pharma, says the anti-GD2 antibody has received the US designation for first-line use alongside induction chemotherapy; it is not approved anywhere.
Renaissance Pharma, part of Essential Pharma, announced on 16 November 2026 that the US Food and Drug Administration has granted Breakthrough Therapy Designation to daretabart, an anti-GD2 antibody.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release: Essential Pharma ↗
Article written by VigiEye from the official source (Essential Pharma). Claims are the company's own. AI-assisted; check the source before acting.
More Regulatory
All →
Galectin files belapectin Phase 3 protocol with FDA as chairman converts $105.8M debt
🇺🇸 Galectin Therapeutics Inc (GALT) · Mon 16 Nov 2026
Apnimed's sleep apnoea drug AD109 awaits FDA decision with 28 February 2027 goal date
🇺🇸 Apnimed, Inc. (APMD) · Mon 16 Nov 2026
FDA sets 25 March 2027 goal date for Unicycive's resubmitted oxylanthanum carbonate application
🇺🇸 Unicycive Therapeutics, Inc. (UNCY) · Mon 16 Nov 2026
FDA grants orphan drug designation to Noema's basimglurant for trigeminal neuralgia
Noema Pharma AG · Mon 16 Nov 2026
FDA issues complete response letter for Summit's ivonescimab in EGFR-mutant NSCLC
🇺🇸 Summit Therapeutics Inc. (SMMT) · Mon 16 Nov 2026
Invivyd Q3 Pemgarda revenue reaches $15.4M as VYD2311 data timing shifts after FDA talks
🇺🇸 Invivyd, Inc. (IVVD) · Mon 16 Nov 2026